Clinical trial
A Study Comparing the Efficacy and Safety of OROS® Oxybutynin to That of…
NCT00269750 · Alza Corporation, DE, USA, Industry · Completed
Key facts
| NCT number | NCT00269750 |
|---|---|
| Title | A Study Comparing the Efficacy and Safety of OROS® Oxybutynin to That of Ditropan® (Immediate-release Oxybutynin) for the Treatment of Patients With Urge or Mixed Urinary Incontinence. |
| Official title | The Maximum Tolerated Dose and Minimum Effective Dose of OROS® Oxybutynin Compared to Ditropan® (Immediate-release Oxybutynin) in the Treatment of Patients With Urge or Mixed Urinary Incontinence |
| Lead sponsor | Alza Corporation, DE, USA, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Urge Incontinence |
| Intervention type | Drug |
| Interventions | OROS® oxybutynin or Ditropan® |
| Enrollment | 100 |
| Start date | Jul 1, 1996 |
| Completion | Feb 1, 1997 |
| First posted | Dec 26, 2005 |
| Last update posted | May 19, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: